Disease Spotlight: Prostate Cancer

Based on results from the phase III PSMAddition trial, the expanded approval may nearly double the number of patients with prostate cancer who can be treated with Pluvicto.

For biopsy-naïve patients who had radical prostatectomy for prostate cancer, new research suggests that biparametric MRI is comparable to multiparametric MRI for detecting extraprostatic extension.

Researchers said the combination of 18F-flotufolastat PET/MRI may lead to a 57 percent reduction of prostate biopsies in comparison to a 25 percent reduction with prostate MRI alone.

For men with high clinical risk for prostate cancer (PCa) and a lack of significant findings on mpMRI, triage use of PSMA PET/CT resulted in a 49 percent reduction of biopsies and an 18 percent reduction in detection of clinically insignificant PCa, according to newly published research.

While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

Patients with PRECISE 4 or 5 scores based on prostate MRI had over a 4.5-fold higher likelihood of biopsy progression in comparison to those with PRECISE 1-3 scores, according to a new multicenter study involving over 1,600 patients.

Patients who had a total tumor volume (TTV) complete response (CR) on six-week SPECT/CT imaging had a 16 percent higher survival rate at two years in comparison to those who didn’t have TTV CR, according to new prospective research.

Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.

Pre-op MRI detection of seminal vesicle invasion was associated with a greater than five times higher likelihood of metastatic failure for patients undergoing radical prostatectomy, according to a newly published meta-analysis.

In a recent interview, Louise Emmett, MBChB, FRACP, FAANMS, MD, discussed recent findings from the Co-PSMA trial demonstrating enhanced detection of biochemical recurrence of prostate cancer with the PET agent 64Cu-SAR-bisPSMA.

Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerging theranostics be effective in other targets beyond PSMA? Daniel George, M.D., addressed these topics and more in a recent interview.

Emerging PSMA PET-based nomograms offered 12 percent and 14 percent higher AUCs than the European Association of Urology risk score for risk stratification of patients with biochemical recurrence of prostate cancer, according to an international, registry-based study involving over 11,000 patients.

Designed to enhance product stability at higher radioactive concentrations, the PSMA PET imaging agent Pylarify TruVu (piflufolastat F 18) may facilitate enhanced supply flexibility and access for men with suspected recurrence or metastasis of prostate cancer.

In a recent interview, Ashesh Jani, M.D., discussed pertinent findings in two post-hoc studies from the SPOTLIGHT trial that examined the efficacy of 18F-flotufolastat PET/CT for detecting biochemical recurrence and bone metastases in patients with prostate cancer.

In a recent interview, Brian Helfand, M.D., Ph.D., discussed key findings from a multicenter prospective trial, presented at the ASCO-GU symposium, that compared the PET radiotracers 18F-flotufolastat and 18F piflufolastat for urinary radioactivity and detection of PCa recurrence.

In a recent interview from the ASCO-GU conference. Daniel George, M.D., discussed new study findings with 177Lu-PSMA-617 for the treatment of older taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and potential implications for future research.

New MRI research suggests that adjunctive AI may lead to a significant reduction of unnecessary prostate biopsies.

In comparison to 68Ga-PSMA-11, 64Cu-SAR-bisPSMA more than doubled the rate of detection for prostate cancer recurrence and facilitated changes to the treatment plan in 44 percent of patients, according to research to be presented at the upcoming European Association of Urology (EAU) Congress.

In a recent interview, Gary Ulaner, M.D., Ph.D., discussed preliminary research with the newly patented 61Cu-NU101 radiodiagnostic agent and the potential with the agent’s half-life in expanding access to molecular imaging for prostate cancer detection.

Researchers found that PSMA PET/CT offered 18 percent higher accuracy than mpMRI in detecting bilateral intraprostatic disease, according to a new study involving patients with intermediate or high-risk prostate cancer.

A high SUVmean on PSMA PET imaging was associated with 95 more days of mean progression-free survival (PFS) in contrast to those with a low median SUVmean, according to a new study of patients with mCRPC treated with (225Ac)Ac-PSMA-I&T.

Employing AI-powered automation, the MIM LesionID™ Pro reportedly bolsters the efficiency of whole-body tumor burden analysis with PSMA PET/CT and SPECT/CT.

The use of 5T prostate MRI offered significantly higher signal-to-noise ratio (SNR) than 3T prostate MRI as well as enhanced delineation with T2-weighted and diffusion-weighted imaging, according to newly published comparative research.

In recent interviews, Rajesh Bhayana, M.D., Manisha Bahl, M.D., and Jeremie Calais, M.D., Ph.D., shared their thoughts on agentic AI, key directions in breast imaging research and emerging trends with prostate cancer theranostics in 2026.